An Alternate Future

We exist to create an alternate future for people with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory for people living with these debilitating diseases.

First-in-class therapies to treat neurodegenerative disease

Alterity is developing first-in-class therapies to treat neurodegenerative disease. Our lead drug candidate, ATH434, has demonstrated efficacy in several animal models of Parkinsonian disorders and is being evaluated in clinical trials.

Our therapies

News

Alterity Therapeutics to Participate in the Benchmark Company Healthcare House Call Conference

May 26, 2022May 26, 2022

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing diseas

Appendix 4C – Q3 FY22 Quarterly Cash Flow Report

April 29, 2022April 29, 2022

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developin

Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in the United Kingdom

April 27, 2022April 27, 2022

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) today announced that the United Kingdom Medicines &

Appendix 4C – Q1 FY22 Quarterly Cash Flow Report

October 29, 2021October 29, 2021

Highlights: New details on ATH34 Phase 2 clinical trial released. Data from bioMUSE presented at International Parkinson and Movement Disord